(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual revenue growth rate of 37.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.72%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.78%.
Zevra Therapeutics's revenue in 2025 is $84,388,000.On average, 10 Wall Street analysts forecast ZVRA's revenue for 2026 to be $8,276,300,620, with the lowest ZVRA revenue forecast at $7,249,433,582, and the highest ZVRA revenue forecast at $9,954,530,139. On average, 9 Wall Street analysts forecast ZVRA's revenue for 2027 to be $12,769,406,889, with the lowest ZVRA revenue forecast at $9,528,357,799, and the highest ZVRA revenue forecast at $17,633,513,913.
In 2028, ZVRA is forecast to generate $17,179,755,781 in revenue, with the lowest revenue forecast at $13,274,395,778 and the highest revenue forecast at $22,575,311,535.